推荐产品
等级
pharmaceutical primary standard
API类
flucytosine
制造商/商品名称
EDQM
mp
298-300 °C (dec.) (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
NC1=NC(=O)NC=C1F
InChI
1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
InChI key
XRECTZIEBJDKEO-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Flucytosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
具有抗真菌活性的核苷类似物。 5-FC由胞嘧啶脱氨基酶脱氨，可产生5-氟尿嘧啶，导致RNA密码错编。 5-氟尿嘧啶可抑制DNA和RNA的合成，干扰核糖体蛋白质合成。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
其他客户在看
Angela Loyse et al.
The Journal of antimicrobial chemotherapy, 68(11), 2435-2444 (2013-06-22)
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice. However, access to flucytosine in Africa and Asia, where disease burden
[Flucytosine - a classical partner for combination therapy].
Annemarie Polak
Mycoses, 45 Suppl 3, 31-33 (2003-04-15)
P Francis et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 15(6), 1003-1018 (1992-12-01)
Flucytosine is an antifungal agent useful in combination with amphotericin B in the treatment of several deeply invasive mycoses. The potentially dose-limiting, hematologic, gastrointestinal, and hepatic toxicities of flucytosine lead to a reluctance to use it in myelosuppressed patients. To
W L Whelan
Critical reviews in microbiology, 15(1), 45-56 (1987-01-01)
In terms of genetically determined susceptibility to the clinical antifungal agent 5-fluorocytosine (5-FC), Candida albicans may be homozygous sensitive (FCY/FCY), homozygous resistant (fcy/fcy), or heterozygous (fcy/FCY). Although heterozygotes are only slightly resistant, they occur at significant frequency among clinical strains
J E Bennet
Annals of internal medicine, 86(3), 319-321 (1977-03-01)
Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all three diseases has
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门